

USER GUIDE

NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUCTM)

Access to the NCCN Imaging AUC[™] is free.

Prior to accessing NCCN Imaging AUC[™] users must accept an End-User License Agreement (EULA) and create a free account or login with an existing account on NCCN.org.

About NCCN Imaging AUC[™]

NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC[™]) include information designed to support clinical decision-making around the use of imaging in patients with cancer and are based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]).

NCCN Imaging AUC[™] include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance. Additional information includes the indication, imaging modality, and frequency of use, as well as clinical notes related to the specific recommendation. NCCN Imaging AUC[™] also document information on disease stage and histology. All imaging procedures recommended in the NCCN Guidelines[®], including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT) and ultrasound, are included within NCCN Imaging AUC[™].

NCCN Imaging AUC[™] are accessible through an easy to use web-based user interface. The NCCN Imaging AUC[™] include a full complement of imaging AUC in oncology care. NCCN, a CMS-approved Provider Led Entity (PLE), is committed to assuring that the most up-to-date recommendations are available and reviews and updates NCCN Imaging AUC[™] on a continual basis to ensure that the recommendations take into account the most current evidence.

NCCN.org/imagingAUC

The top menu of the NCCN Imaging AUC[™] contains various drop-down lists for displaying the database (left) and various sorting fields (right).

| National Comprehensive Cancer Network* | NCCN Imaging Appropria | te Use Criteria™ | The NCCN Im | Printed by Briana O'Donnell on 4112019 2.13 PM. For personal use only. Not approved for distribution. gring Appropriate Use Criteria™ is copyrighted by the National Comprehensive Cancer Network, Inc. All r About the NCCN Imaging Appropriate Use Criteria™ |
|---|---|--|-----------------------------------|--|
| ✤ Options | | | | |
| se the drop-down menus to se | arch the database: | Fields | to display/hide: | |
| NCCN Guideline: | Select a NCCN Guideline v | | 0-10 Codes | Frequency |
| Clinical Setting | Online of Olivian Online | Star | ge | Imaging Notes |
| Clinical Setting: | Select a Clinical Setting 🔻 | Ad | ditional Description of Stage | Guideline Page |
| Purpose: | Select a Purpose 🔻 | I, I | N, M | Uisplay All |
| | | | lology | |
| Modality: | Select a Modality 🔻 | | | |
| ICD-10: | Select an ICD-10 Code v | | | |
| | Reset Filters | boxes. Or check Display | All to view data for | all available fields. |
| o display the <i>i</i> ou can further | AUC of your choice, sele r filter by Imaging Modal | ect either an NCCN Guide ity, Test Purpose, or ICD- | ine or Clinical S 10 Code. | etting to match your interest. |
| National Comprehensive Cancer Network* | NCCN Imaging Appropriat | e Use Criteria TM NCCN Nation | al Comprehensive NCCN Network* | Imaging Appropriate Use Criteria™ |
| Options | | | | |
| the dron-down menus to see | rch the database | Use the drop-do | own menus to search the database | |
| and an op-down menua to sea | ion die dataJubb. | | | |

| Use the drop-down menus to sea | rch the database: | Use the drop-dov | Use the drop-down menus to search the database: | | | | |
|--------------------------------|---|----------------------|---|---|--|--|--|
| NCCN Guideline: | Select a NCCN Guideline 🔻 | NCCN | Guideline: | Breast Cancer v.4.2018 | | | |
| Clinical Setting: | Select a NCCN Guideline Acute Lymphoblastic Leukemia v.1.2018 Acute Myeloid Leukemia v.1.2019 | Clinic | cal Setting: | Breast Cancer - Inflammatory Breast Cancer 🔻 | | | |
| Purpose: | AIJCS-Related Kaposi Sarcoma v.1.2019 Anal Carcinoma v.1.2018 Basal Cell Skin Cancer v.1.2019 | | Purpose: | Diagnostic/Staging • | | | |
| Modality: | B-Cell Lymphomas v.1.2019 Bladder Cancer v.1 Bone Cancer v.1 | | Modality: | - Select a Modality - | | | |
| ICD-10: | Breast Cancer Breast Cancer Cancer-Associ Certral Nervot Certral Cancer Chronic Lympt | Irposes e will be | ICD-10: | Bone Scan CT Mammogram MRI PET/CT Ultrasound | | | |

When first selecting a disease or resetting the filters, the data table will display certain default data fields, including: Clinical Setting, Guideline Page, Category of Evidence, Stage, Indication, Imaging Recommendation, Purpose, and Notes. With sorting fields applied, the data table displays the selected NCCN Imaging AUC[™].

| Filter | ters: Breast Cancer v.4.2018 > Breast Cancer - Inflammatory Breast Cancer > Diagnostic/Staging | | | | | | | |
|--------|--|---------------------|----------------------------|----------|---|---|-----------------------|---|
| Det | ault Sort IL Showing | 1 to 2 of 2 entries | | | | | | Search: |
| ₽ | Clinical Setting | Guideline 斗 Page | Category of ↓↑ Evidence | Stage 11 | Indication | Imaging Recommendation | Purpose ^{1†} | Imaging Notes |
| | Inflammatory Breast Cancer | IBC-1 | 2A | | Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup | Diagnostic bilateral mammogram Ultrasound as necessary Breast MRI with contrast (optional) Chest diagnostic CT with contrast Bone scan FDG PET/CT (optional) | Diagnostic | Chest diagnostic CT if pulmonary symptoms present. Breast I exams are performed with IV contrast and require a dedicate breast coil and breast imaging radiologists familiar with the optimal timing sequences and other technical details for imag- interpretation. Breast MRI may be used for staging evaluation define extent of cancer or presence of multifocal or multicentit cancer in the ipsilateral breast, or as screening of the contralateral breast cancer at time of initial diagnosis (categor 2B). There are no high-level data to demonstrate that the use MRI to facilitate local therapy decision-making improves local recurrence or survival. Breast read more |
| | Inflammatory Breast Cancer | IBC-1 | 2B | | Clinical pathologic diagnosis of inflammatory breast | Sodium fluoride (¹⁸F-NaF) PET/CT | Diagnostic | If FDG PET/CT is performed and clearly indicates bone metastasis, bone scan or sodium fluoride PET/CT may not be |

NCCN Imaging AUC[™]

1

2

3

5

NCCN Imaging AUC[™] are built on a responsive platform that can be viewed on mobile devices. If the screen size cannot accommodate all data fields simultaneously, the interface will automatically hide certain fields and indicate this with a red numbered icon in the left most column of the data table.

Filters: Breast Cancer v.4.2018 > Breast Cancer - Inflammatory Breast Cancer > Diagnostic/Staging Default Sort 🖡 Search: Showing 1 to 2 of 2 entries ₽ Clinical Guideline 斗 Category of 1 Imaging Stage Indication Purpose Setting Page Evidence Recommendation An easy-to-Inflammatory IBC-1 2A Clinical pathologic diagnosis of Diagnostic bilateral Diagnostic read view of Breast Cancer inflammatory breast cancer; Initial workup mammogram the selected AUC can be made available Depending on the web browser, the Guideline Page hyperlink will redirect to either the exact for printing NCCN Guidelines page for that recommendation (Internet Explorer, Safari), or to the front page or saving of the NCCN Guidelines (Google Chrome, Firefox) where users can navigate to the appropriate as a PDF by A red numbered page. checking the icon indicates box in the left hidden fields inflammatory breast cancer; Initial workup NaF) PET/CT most column. Chest/Abdominal/Pelvic when viewed on diagnostic CT with mobile devices, contrast tablets, or reduced screen sizes. Click on the icon to view additional fields in a vertical display.

With the desired AUC displayed, individual or multiple records may be selected for printing by checking the printer icon box (left most data field, above). The recommendation is separated into Disease Information and Imaging Recommendation. Print the page or save the record as a PDF.

| _ | | | |
|--|--|--|--|
| CCN National Comprehensive Cancer Network* | ICCN Imaging Appropriate Use Criteria™ | | |
| ad by Briana O'Donnell on 4/1/2019 2:40 PM. For NCCN.org/imaging. | personal use only. Not approved for distribution. The NCCN Imaging Appropriate Use Criteria TM is copyrighted by the National Comprehensive Cancer Network, Inc. All rights reserved. To view the most up-to-date version | | |
| Disease Information | | | |
| Guideline Name: | Breast Cancer | | |
| Clinical Setting: | Inflammatory Breast Cancer | | |
| Stage: | AJCC, 8th Edition | | |
| Indication: | Clinical pathologic diagnosis of inflammatory breast cancer; Initial workup | | |
| Guideline Page: | IBC-1 | | |
| | | | |
| maging Recommendation | | | |
| Category of Evidence: | 2A | | |
| Purpose: | Diagnostic | | |
| Modality: | Diagnostic bilateral mammogram Ultrasound as necessary Breast MRI with contrast (optional) Chest diagnostic CT with contrast Bone scan FDG PET/CT (optional) | | |
| Notes: Chest diagnostic CT if pulmonary symptoms present. Breast MRI exams are performed with IV contrast and require a dedicated breast coil and breast imaging radiologists familiar with the optimal timing sequences and other technical details for image interpretation. Breast MRI may be used for staging evaluation to define extent of cancer or presence of multification or multicentric cancer in the ligilateral breast, or as screening of the contralateral breast cancer at time of initial diagnosis (category 2B). There are no high-level data to demonstrate that the use of MRI to facilitate local therapy decision-markin improves local recurrence or survival. Breast MRI may be helpful for breast cancer evaluation before and after preoperative systemic therapy to define e of disease, response to treatment, and potential for breast-conserving therapy. False-positive findings on breast MRI are common. If FDG PET/CT is performed and clearly indicates bone metastasis, bone scan or solum fluoride PET/CT may not be needed. FDG PET/CT can be performed at the sam time as diagnostic CT. FDG PET/CT is most helpful in situations where standard staging studies are equivocal or suspicious, especially in the setting of locally advanced or metastatic clisease. FDG PET/CT may also be helpful in identifying unsuspected regional nodal disease and/or distant metastases in locally advanced breast cancer when used in addition to standard staging studies. | | | |
| | | | |